ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Clinical trials for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat leukemia: experimental pill joins fight
Disease control Recruiting nowThis early-stage study is testing a new oral drug, SNDX-5613, when given alongside standard chemotherapy for adults newly diagnosed with specific genetic types of acute myeloid leukemia (AML). The main goals are to find the safest and most effective dose of the new combination an…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Scientists test Dual-Attack strategy for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and finding the best dose of a new two-drug combination (SNDX-5613 and gilteritinib) for adults with a specific form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The drugs work together to block two…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENT
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC